Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599216 | 0.84 | SCN9A (0.44) | SCN9ASCN5ACYP3A4CYP2C9SSTR4 | |
| SCHEMBL10324676 | 0.84 | SCN9A (0.44) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL17248008 | 0.81 | NOS3 (0.41) | SCN9ASCN5ASSTR4AAK1 | |
| SCHEMBL365208 | 0.81 | SCN9A (0.47) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL16858566 | 0.81 | SCN9A (0.44) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL17244885 | 0.81 | SCN9A (0.44) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL12037978 | 0.79 | SLC13A5 (0.40) | CYP3A4CYP2C9SSTR4 | |
| SCHEMBL15599250 | 0.79 | SCN9A (0.43) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL19075622 | 0.78 | SCN9A (0.43) | SCN9ASCN5ACYP3A4CYP2C9AAK1 | |
| SCHEMBL16082402 | 0.78 | SCN9A (0.44) | SCN9ASCN5ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2970156-B1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2017091592-A1 | SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS | GENENTECH, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2014153037-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014144545-A2 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885SCN5A 1598/4885CYP3A4 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.